Janus kinase inhibitors
Janus kinase inhibitors (JAK inhibitors, or JAKis) are a class of targeted anti-inflammatory and immunomodulatory therapies that block signaling through the Janus kinase–signal transducer and activator of transcription (JAK-STAT) pathway.
Janus kinase inhibitors (JAK inhibitors, or JAKis) are a class of targeted anti-inflammatory and immunomodulatory therapies that block signaling through the Janus kinase–signal transducer and activator of transcription (JAK-STAT) pathway. The Janus kinase family comprises four members — JAK1, JAK2, JAK3, and tyrosine kinase 2 (TYK2) — which associate with cytokine receptors and phosphorylate STAT transcription factors; individual inhibitors differ in which of these kinases they preferentially block, and that selectivity shapes both their efficacy and their adverse-effect profiles. By suppressing JAK-mediated cytokine signaling, these agents reduce immune activation across a range of inflammatory, autoimmune, and myeloproliferative diseases, including rheumatoid arthritis, atopic dermatitis, alopecia areata, systemic sclerosis, scleritis, drug reaction with eosinophilia and systemic symptoms (DRESS), and myelofibrosis.
Agents in this class include the pan-JAK inhibitor tofacitinib, the JAK1/2 inhibitors baricitinib and ruxolitinib (the latter a mainstay of myelofibrosis therapy), and the more JAK1-selective agents upadacitinib and abrocitinib. Despite differing in selectivity and approved indications, they share the same core principle of suppressing cytokine-driven inflammation. Because JAK signaling is broadly involved in immune and hematopoietic pathways, the class carries a regulatory boxed warning for serious adverse events — including major adverse cardiovascular events, venous thromboembolism, malignancy, and serious infection — so the balance of efficacy, safety, and patient-reported outcomes remains a central focus of ongoing research.
Where the papers sit
14 papers from the last 6 months study janus kinase inhibitors directly · updated from PubMed 12 Nov 2026
Study type 0 clinical trials · 7 observational · 2 human data · 5 unclassified
Themes 3 themes · 1 new direction
-
Rheumatoid Arthritis Outcomes
JAK inhibitor use in rheumatoid arthritis is moving toward treatment-aware assessment of effectiveness, safety, and persistence. Observational cohorts examine renal function-adjusted dosing, age at onset, discontinuation, and factors associated with response. Comparisons with sarilumab and analyses of acute coronary events keep cardiovascular risk central to treatment selection. The recurring goal is individualized prescribing rather than a single preferred inhibitor.
6 papers · 42.9%
-
Alopecia Areata Treatment
Ritlecitinib, tofacitinib, and baricitinib are being compared for alopecia areata across acute, chronic, and paediatric care. Effectiveness is repeatedly assessed with the Severity of Alopecia Tool alongside real-world safety and treatment persistence. Clinician preferences focus on balancing efficacy, safety, dosing, and convenience among approved options. The evidence remains comparative and observational rather than establishing one universally superior JAK inhibitor.
3 papers · 21.4%
-
Others — JAK Inhibitors in Immune Disease
JAK inhibitors are being evaluated across Crohn's disease, systemic sclerosis, systemic autoinflammatory disease, long COVID, and melanoma safety surveillance. Upadacitinib and tofacitinib recur in studies of clinical response, cytokine-driven inflammation, and combination treatment. The evidence spans real-world effectiveness, biologic-JAK combinations, mechanistic biomarkers, and disproportionality signals rather than one shared endpoint. No consistent therapeutic direction emerges across these different diseases and questions.
5 papers · 35.7%
JAK inhibitors are used as components of combination therapy for refractory systemic autoinflammatory disease
The biologic-biologic and biologic-JAK inhibitor combination therapy study in refractory systemic autoinflammatory diseases examined advanced combination therapy rather than JAK-inhibitor monotherapy. Whereas the other papers use JAK inhibitors as individual treatments whose effectiveness, safety, dosing, persistence, or comparative performance is assessed, this study used them together with biologics in patients with refractory disease, evaluating responses through corticosteroid dose, C-reactive protein, and clinical improvement. This gives JAK inhibitors a distinct role as part of combination immunosuppression for difficult-to-control systemic autoinflammatory disease 42691741Sep.
Papers
The 14 papers from the last 6 months that study janus kinase inhibitors directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.
By theme
Rheumatoid Arthritis Outcomes (6)
- Renal function-adjusted initial JAK inhibitor dosing and outcomes in rheumatoid arthritis: from the ANSWER cohort study. Clinical rheumatology · 28 Sept 2026 PMID 42806188
- Effectiveness and safety of Janus Kinase inhibitors in patients with rheumatoid arthritis, results from a multicenter observational "real-life" GIRRCS (Gruppo Italiano di Ricerca in Reumatologia Clinica e Sperimentale) study. Clinical rheumatology · 2 Sept 2026 PMID 42684557
- Factors associated with the effectiveness and safety of Janus kinase inhibitors in rheumatoid arthritis: an 8-year observational study from the JAGUAR Registry. RMD open · 31 Aug 2026 PMID 42674814
- Factors associated with discontinuation of bDMARDs and JAK inhibitors in patients with rheumatoid arthritis: a retrospective study. Clinical rheumatology · 13 Aug 2026 PMID 42587227
- Janus kinase inhibitor exposure and acute coronary event patterns in rheumatoid arthritis: a treatment-aware retrospective study. Clinical rheumatology · 24 Jul 2026 PMID 42498889
- Comparative effectiveness and safety of sarilumab vs Janus kinase inhibitors in late- and younger-onset rheumatoid arthritis. Rheumatology (Oxford, England) · 9 Jun 2026 PMID 42261260
Alopecia Areata Treatment (3)
- Real-World Outcomes and Safety of JAK Inhibitors in Paediatric Alopecia Areata: A Retrospective Multicentre Study. The Australasian journal of dermatology · 5 Aug 2026 PMID 42552762
- A Discrete Choice Experiment of Clinician Preferences Among Attributes of Approved Janus Kinase Inhibitors for Alopecia Areata. Advances in therapy · 20 Jul 2026 PMID 42474702
- Comparative Efficacy of JAK Inhibitors in Acute vs Nonacute Alopecia Areata: A Retrospective Cohort Study. Acta dermato-venereologica · 26 May 2026 PMID 42186168
Others — JAK Inhibitors in Immune Disease (5)
- Effectiveness and Safety of Janus Kinase Inhibitors in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis of Real-world Studies. Digestion · 7 Nov 2026 PMID 42998267
- Cutaneous melanoma and JAK inhibitors: a disproportionality analysis in EudraVigilance. European journal of clinical pharmacology · 13 Oct 2026 PMID 42870108
- Biologic-biologic and biologic-JAK inhibitor combination therapy in refractory systemic autoinflammatory diseases. Seminars in arthritis and rheumatism · 3 Sept 2026 PMID 42691741
- Cytokine-Driven Hyperinflammation in Long COVID: Mechanisms, Biomarkers, Complement Dysregulation, and Emerging Immunotherapies-A Narrative Review. Health science reports · 27 Aug 2026 PMID 42657238
- Longitudinal clinical response to Janus kinase inhibitors in systemic sclerosis: a real-life multicentric study across multiple clinical domains. Clinical rheumatology · 30 May 2026 PMID 42217099
By study type
Observational studies and case reports (7)
- Renal function-adjusted initial JAK inhibitor dosing and outcomes in rheumatoid arthritis: from the ANSWER cohort study. Clinical rheumatology · 28 Sept 2026 PMID 42806188
- Biologic-biologic and biologic-JAK inhibitor combination therapy in refractory systemic autoinflammatory diseases. Seminars in arthritis and rheumatism · 3 Sept 2026 PMID 42691741
- Effectiveness and safety of Janus Kinase inhibitors in patients with rheumatoid arthritis, results from a multicenter observational "real-life" GIRRCS (Gruppo Italiano di Ricerca in Reumatologia Clinica e Sperimentale) study. Clinical rheumatology · 2 Sept 2026 PMID 42684557
- Factors associated with the effectiveness and safety of Janus kinase inhibitors in rheumatoid arthritis: an 8-year observational study from the JAGUAR Registry. RMD open · 31 Aug 2026 PMID 42674814
- Factors associated with discontinuation of bDMARDs and JAK inhibitors in patients with rheumatoid arthritis: a retrospective study. Clinical rheumatology · 13 Aug 2026 PMID 42587227
- Janus kinase inhibitor exposure and acute coronary event patterns in rheumatoid arthritis: a treatment-aware retrospective study. Clinical rheumatology · 24 Jul 2026 PMID 42498889
- Comparative Efficacy of JAK Inhibitors in Acute vs Nonacute Alopecia Areata: A Retrospective Cohort Study. Acta dermato-venereologica · 26 May 2026 PMID 42186168
Human data, design not indexed (2)
- Cutaneous melanoma and JAK inhibitors: a disproportionality analysis in EudraVigilance. European journal of clinical pharmacology · 13 Oct 2026 PMID 42870108
- A Discrete Choice Experiment of Clinician Preferences Among Attributes of Approved Janus Kinase Inhibitors for Alopecia Areata. Advances in therapy · 20 Jul 2026 PMID 42474702
Unclassified: not yet indexed with MeSH (5)
- Effectiveness and Safety of Janus Kinase Inhibitors in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis of Real-world Studies. Digestion · 7 Nov 2026 PMID 42998267
- Cytokine-Driven Hyperinflammation in Long COVID: Mechanisms, Biomarkers, Complement Dysregulation, and Emerging Immunotherapies-A Narrative Review. Health science reports · 27 Aug 2026 PMID 42657238
- Real-World Outcomes and Safety of JAK Inhibitors in Paediatric Alopecia Areata: A Retrospective Multicentre Study. The Australasian journal of dermatology · 5 Aug 2026 PMID 42552762
- Comparative effectiveness and safety of sarilumab vs Janus kinase inhibitors in late- and younger-onset rheumatoid arthritis. Rheumatology (Oxford, England) · 9 Jun 2026 PMID 42261260
- Longitudinal clinical response to Janus kinase inhibitors in systemic sclerosis: a real-life multicentric study across multiple clinical domains. Clinical rheumatology · 30 May 2026 PMID 42217099
Written from 14 PubMed abstracts, each one listed by PMID above. Published: 2026-06-15. Last written: 2026-09-02 by GPT. Drafted by language models from published abstracts; not medical advice.